PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Growth Capital Ventures (GCV) is a Financial Conduct Authority (FCA) approved fintech company. GCV's mission is to back the game changers, innovators and value creators. It is operating at three different levels namely, G-Ventures, a specialist software development division; Quva, a private investor network; and G- Labs, an innovation lab. The company aims to provide investors with access to well researched alternative investment opportunities that are selected for their potential to deliver better returns than traditional mainstream investment products. GCV has structured property transactions worth £14.7 million, has 5000+ everyday investors, and seen 500+ jobs created by portfolio companies. GCV will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,295,410
MyT is a cloud-powered subscription-based accounting software designed for small businesses that allows them to submit financial information to Her Majesty's Revenue and Customs (HMRC) under the Making Tax Digital initiative, which is mandatory from April 2023. MyT asserts that its app provides businesses with a simple way to keep track of business finances on the go, send and manage invoices and bills, and record expenses and mileage. The company claims that its app is available on App Store and Google Play and has witnessed 1000+ downloads to date. It claims that it has onboarded over 500 users without any extensive marketing spend. MyT will use half of the investment to implement its marketing plan, a third for developing new technology and the remaining for administrative expenses.
days to go:
Expired
investment:
£133,543
A multi-award winning investment platform providing customers with ISA eligible loans. Crowdstacker are fully FCA regulated and set a record for the largest crowdfunded P2P loan in the UK, valued at £15m. With the recent release of Innovative Finance ISA, the company is expecting to see rapid growth in the near future.
days to go:
Expired
investment:
£818,210
An online comparison portal focusing on financial, insurance and utility products serving the Latin American market.
days to go:
Expired
investment:
£288,620
Abundance is an alternative finance platform that lets people get directly involved in the transition to 'Net Carbon Zero' by enabling them to engage in 'Green Investments'. The company has a base of 6,800 customers who collectively share a desire to create a greener world. Abundance launched its new product 'Community Municipal Investments' (CMI) in July 2020. Its first investment with West Berkshire Council already has over 400 investors. It has also launched other financial products such as 'Innovative Finance' Individual Savings Account (ISA) and a Self-Invested Personal Pension (SIPP). Abundance has already put over £100 million into green energy and green social housing projects. It will use the investment to establish CMIs as the way to fund councils and engage citizens in green activities, cement its position in 'Net Zero' investments, and secure a strategic partner to grow more quickly.
days to go:
Expired
investment:
£702,620
Enoron is a management system that allows lawyers to easily manage all their clients and all their related information, all their matters and deadlines, keeping track of all their activities, timesheets and accounting and much more.
days to go:
Expired
investment:
£31,896
